Medigene AG (ETR:MDG1 – Get Free Report)’s stock price was up 2.5% during trading on Wednesday . The company traded as high as €1.59 ($1.73) and last traded at €1.58 ($1.72). Approximately 6,863 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 306,207 shares. The stock had previously closed at €1.54 ($1.67).
Medigene Trading Up 4.9 %
The company has a debt-to-equity ratio of 12.95, a current ratio of 2.39 and a quick ratio of 5.85. The company has a 50-day moving average of €1.59 and a 200 day moving average of €1.57. The company has a market cap of $11.99 million, a PE ratio of -2.66, a price-to-earnings-growth ratio of 7.12 and a beta of 0.84.
About Medigene
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
Featured Stories
- Five stocks we like better than Medigene
- Are Penny Stocks a Good Fit for Your Portfolio?
- Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback
- How to Short Nasdaq: An Easy-to-Follow Guide
- JPMorgan: The ‘NVIDIA of Banking’ Poised for More Gains?
- When to Sell a Stock for Profit or Loss
- Buy the Chewy Stock Reversal? Here’s Why Now Is the Time
Receive News & Ratings for Medigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigene and related companies with MarketBeat.com's FREE daily email newsletter.
